Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders

NCT06549114 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT06549114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06549114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 21, 2024
Completion date
November 30, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency disorders (pids)